4,6-dichloro-2-methylsulfanylpyrimidine-5-carboxylic acid benzylamide | 877125-88-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4,6-dichloro-2-methylsulfanylpyrimidine-5-carboxylic acid benzylamide
• 英文别名: N-benzyl-4,6-dichloro-2-(methylthio)pyrimidine-5-carboxamide；N-benzyl-4,6-dichloro-2-methylsulfanylpyrimidine-5-carboxamide
• CAS: 877125-88-7
• 化学式: C₁₃H₁₁Cl₂N₃OS
• 分子量: 328.222
• InChiKey: SJXFVWHMSYNKHQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  80.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4,6-dichloro-2-methylsulfanylpyrimidine-5-carboxylic acid benzylamide 、 6-氨甲基螺[2.5]辛烷 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 10.0h， 生成
  参考文献：
  名称：

  4-Amino-2-cyanopyrimidines: Novel scaffold for nonpeptidic cathepsin S inhibitors

  摘要：

  We describe here a novel 4-amino-2-cyanopyrimidine scaffold for nonpeptidomimetic cathepsin S selective inhibitors. Some of the synthesized compounds have sub-nanomolar potency and high selectivity toward cathepsin S along with promising pharmacokinetic and physicochemical properties. The key structural features of the inhibitors consist of a combination of a spiro[2.5]oct-6-ylmethylamine P2 group at the 4-position, a small or polar P3 group at the 5-position and/or a polar group at the 6-position of the pyrimidine. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.07.011
• 作为产物：
  描述：

  苄胺 、 4,6-dichloro-2-methylsulfanylpyrimidine-5-carbonyl chloride 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 4,6-dichloro-2-methylsulfanylpyrimidine-5-carboxylic acid benzylamide
  参考文献：
  名称：

  [EN] COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS
  [FR] COMPOSES ET COMPOSITIONS UTILISES COMME INHIBITEURS DE LA CATHEPSINE S

  摘要：

  本发明涉及使用式(I)的2-氰基嘧啶化合物，其中R1、R2、R3和X如规范和权利要求中定义的那样，以自由形式或盐形式，并在可能的情况下以互变异构形式，作为猫hepsin S活性的抑制剂。

  公开号：

  WO2006018284A1

文献信息

• COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS
  申请人：Hart Terance William

  公开号：US20090048230A1

  公开（公告）日：2009-02-19

  The present invention relates to the use of a 2-cyanopyrimidine compound of the formula wherein R 1 , R 2 , R 3 and X are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in tautomeric form, as an inhibitor of the activity of cathepsin S.

  本发明涉及使用式中R1、R2、R3和X如规范和权利要求中定义的2-氰基嘧啶化合物的自由形式或盐形式及在可能的情况下互变异构体形式，作为猫hepsin S活性的抑制剂。
• Compounds and compositions useful as cathepsin S inhibitors
  申请人：Novartis AG

  公开号：US07704996B2

  公开（公告）日：2010-04-27

  The present invention relates to the use of a 2-cyanopyrimidine compound of the formula wherein R1, R2, R3 and X are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in tautomeric form, as an inhibitor of the activity of cathepsin S.

  本发明涉及使用式中R1、R2、R3和X如说明书和权利要求中所定义的2-氰基嘧啶化合物，以自由形式或盐形式，并在可能的情况下以互变异构体形式，作为猫蛋白S活性的抑制剂。
• US7704996B2
  申请人：——

  公开号：US7704996B2

  公开（公告）日：2010-04-27
• [EN] COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS<br/>[FR] COMPOSES ET COMPOSITIONS UTILISES COMME INHIBITEURS DE LA CATHEPSINE S
  申请人：NOVARTIS AG

  公开号：WO2006018284A1

  公开（公告）日：2006-02-23

  The present invention relates to the use of a 2-cyanopyrimidine compound of the formula (I), wherein R1, R2, R3 and X are as defined in the specification and in the claims, in free form or in salt form, and , where possible, in tautomeric form, as an inhibitor of the activity of cathepsin S.

  本发明涉及使用式(I)的2-氰基嘧啶化合物，其中R1、R2、R3和X如规范和权利要求中定义的那样，以自由形式或盐形式，并在可能的情况下以互变异构形式，作为猫hepsin S活性的抑制剂。
• 4-Amino-2-cyanopyrimidines: Novel scaffold for nonpeptidic cathepsin S inhibitors
  作者：Osamu Irie、Fumiaki Yokokawa、Takeru Ehara、Atsuko Iwasaki、Yuki Iwaki、Yuko Hitomi、Kazuhide Konishi、Masashi Kishida、Atsushi Toyao、Keiichi Masuya、Hiroki Gunji、Junichi Sakaki、Genji Iwasaki、Hajime Hirao、Takanori Kanazawa、Keiko Tanabe、Takatoshi Kosaka、Terance W. Hart、Allan Hallett

  DOI：10.1016/j.bmcl.2008.07.011

  日期：2008.8

  We describe here a novel 4-amino-2-cyanopyrimidine scaffold for nonpeptidomimetic cathepsin S selective inhibitors. Some of the synthesized compounds have sub-nanomolar potency and high selectivity toward cathepsin S along with promising pharmacokinetic and physicochemical properties. The key structural features of the inhibitors consist of a combination of a spiro[2.5]oct-6-ylmethylamine P2 group at the 4-position, a small or polar P3 group at the 5-position and/or a polar group at the 6-position of the pyrimidine. (C) 2008 Elsevier Ltd. All rights reserved.